Kairos Pharma, Ltd. (KAPA)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $1.54M
Last updated: Nov 17, 2026 at 11:03 AM ET
Kairos Pharma, Ltd. (KAPA) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Kairos Pharma reported EPS of -$0.59, above the -$0.63 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KAPA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 9 quarters below that had an estimate, KAPA beat 2, missed 6 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2024, when EPS landed 400.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.59 | -$0.63 | -$0.63 - -$0.63 | +6.35% | Beat | N/A | 1 | 0 up, 0 down | Nov 13, 2026 |
| Jun 30, 2026 | -$0.06 | -$0.09 | -$0.09 - -$0.09 | +33.33% | Beat | N/A | 1 | 0 up, 0 down | Aug 12, 2026 |
| Mar 31, 2026 | -$0.56 | -$0.49 | -$0.49 - -$0.49 | -14.29% | Miss | N/A | 1 | 0 up, 0 down | May 13, 2026 |
| Dec 31, 2025 | -$0.07 | $0.03 | $0.03 - $0.03 | -333.33% | Miss | N/A | 1 | 0 up, 0 down | Mar 31, 2026 |
| Sep 30, 2025 | -$0.07 | -$0.07 | -$0.10 - -$0.05 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 14, 2025 |
| Jun 30, 2025 | -$0.08 | -$0.05 | -$0.05 - -$0.05 | -60.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 12, 2025 |
| Mar 31, 2025 | -$0.03 | -$0.02 | N/A | -50.00% | Miss | N/A | N/A | N/A | Apr 15, 2025 |
| Dec 31, 2024 | -$0.05 | -$0.02 | -$0.02 - -$0.02 | -150.00% | Miss | N/A | 1 | 0 up, 0 down | Feb 26, 2025 |
| Sep 30, 2024 | -$0.10 | -$0.02 | N/A | -400.00% | Miss | N/A | N/A | N/A | Nov 14, 2024 |
| Jun 30, 2024 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 28, 2024 |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$1.21 | N/A |
| Jun 30, 2026 | -$0.62 | N/A |
| Dec 31, 2025 | -$0.25 | N/A |
| Jun 30, 2025 | -$0.16 | N/A |
| Dec 31, 2024 | -$0.17 | N/A |
Frequently Asked Questions About KAPA
Did KAPA beat earnings estimates last quarter?
Yes. Kairos Pharma reported EPS of -$0.59 for the quarter ended Sep 30, 2026, above the -$0.63 estimate, a 6.35% surprise.
What EPS do analysts expect from KAPA next quarter?
The consensus EPS estimate for Kairos Pharma for the quarter ending Dec 31, 2026 is -$0.64 from 4 analysts, with estimates from -$0.75 to -$0.51.
How often does KAPA beat earnings estimates?
Kairos Pharma beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -70.99%.
KAPA pages: Overview, Earnings, Forecast, Financials, Competitors